Elixinol Global Ltd (ELLXF)

[ShtockMahket]

So, basically:
-31% revenue decline QoQ
-Dramatically increased inventory in anticipation of an expected increase in consumer demand
-Improved balance sheet from Q4 (IIRC), cash of 27.4m
-Signed an agreement with Presence Marketing to gain shelf placement and support product sales on an ongoing basis throughout the US.
-Partnered with Multiply, "a nationally recognised PR and Analytics Agency"
-Received an order for 13 SKUs from a large brick and mortar national retailer initially across 330 stores; expecting a rollout to over 1000 US stores
In the UK:
-Reached an agreement with Cambrian Alliance Group, which has over 1200 member pharmacies, rollout commenced in April
-Entered into a sales and distribution agreement with a major distributor; they received a purchase order for 60,000 units of 6 SKUs for distribution across 250 stores
In AU:
-Still no update on licensing for Nunyara

They justify the revenue decrease as "driven by Elixinol’s strategic decision to reduce focus on low margin private label business in the US to enable increased capacity for expected future growth of higher margin branded products and provide the ability to capture further market share."

Don't know how much of the distribution news is new, but tomorrow is likely to be a decline. EXL currently down over 3%.